Hormonal
GLP-1 receptor agonists (GLP-1 RAs) induce significant gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) by slowing gastric emptying and increasing gastric accommodation, with incidence rates ranging from 18% to 52% depending on the specific agent and dose.
If you are prescribed a GLP-1 drug like semaglutide or liraglutide, expect a high chance of nausea or vomiting, especially when starting. The paper advises starting at the lowest dose and increasing slowly. Crucially, you must adjust your diet: eat smaller meals, reduce fat, and avoid raw fiber. If you continue to have side effects, ask your doctor about dose de-escalation. Do not assume the sickness is what causes the weight loss; the drug works directly, but the side effects are a common hurdle to manage.
The most common reported adverse effects (AEs) with these incretin RAs are gastrointestinal symptoms that include nausea, vomiting, diarrhea, and constipation... In the SUSTAIN 10 trial with SQ semaglutide, 52% patients reported gastrointestinal AEs compared to 35% in the placebo group... Oral semaglutide (approved for treatment of T2DM), 25mg and 50mg per day, was associated with nausea in 27% and vomiting in 18% of patients.
Why this rating
Based on multiple randomized controlled trials (SUSTAIN, PIONEER, SURMOUNT) and meta-analyses cited in the review.
Source
Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice
Michael Camilleri et al. · The American Journal of Gastroenterology · 2023
DOI 10.14309/ajg.0000000000002519
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →